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canetti each carry a species-specific combination of spacers, allowing 
easy recognition of these species by spoligotyping. The function of 
the DR locus is unknown, but not essential for growth, as DR 
knockout mutants are viable. The existence of D R  loci in other 
bacterial species and their potentlal use in epidemiology will be 
discussed. 
Resistant bacteria-their evolution and 
pharmacodynamic response to 
antimicrobials 
Fitness costs of resistance and genetic 
compensation 
D. Anderson. Suedish Institute f o r  Infectious Diseases Control, Solna, 
Sweden 
The rate of development and stability of antibiotic resistance are 
determined by several factors, most of which have not been studied 
in any detail. For example, bacterial population sizes, mutation rates, 
antibiotic concentration heterogeneities in hosts, fitness costs of 
resistance, and the ability of bacteria to genetically compensate for 
such costs, are factors that will affect resistance dynamics. Of parti- 
cular interest are fitness costs and the amelioration of these costs by 
compensatory mutations. We have studied several types of chromo- 
somal resistances (due to target modifications) in several species of 
pathogenic bacteria. Results show that in most cases resistant bacteria 
are less fit, both in animal models and under laboratory conditions. 
However, this picture is con~plicated by the rapid appearance of 
compensatory mutations that restore fitness without loss of resistance. 
Thus, compensatory mutations could stabilize a resistant population 
and make resistance irreversible. 
Combination therapy as a tool to prevent 
emergence of resistance. What can be learnt 
from in vitro models? 
J.W. Mouton. Cunisius USlhelmina Hospital, Dept. ofMicrobiology, 
Ni jmepn,  The  Netherlands 
One of the possible strategies to prevent emergence of resistance is 
the use of combination therapy. In vitro pharmacokinetic models can 
be used to simulate various dosing regimens of the combinations, 
both to determine the optimal regimens to be used and to obtain 
insight into the selection process of resistant bacteria during those 
regimens. Most of the (few) studies performed show that, if resistance 
emerges during monotherapy, this can be prevented by the use of a 
combination. Experiments where Pseudomonus aenrginosa is treated 
with beta-lactani-aminoglycoside combinations indicate that this 
could be partly due to the supplementary kill by the aminoglycoside 
reducing the inoculum. The same conclusions can be drawn for the 
quinolone-beta-lactam combinations. By using inocula of two 
different strains with different MICs in various proportions, more 
insight is gained into this process. 
Progress in meningitis 
From gene to disease: the example of 
pneumococcal meningitis 
E. Tuomanen. S t l u d e  (ChiIdrenS Research) Hospital, Memphis, TN, 
USA 
The pneuinococcus adheres to activated blood-brain barrier 
endotheliaI cells via the PAF receptor, an interaction that enables 
endocytosis to occur. This route of entry to the central nervous 
system (CNS) involves a novel recyling route of trafficking and 
depends on the bacterial surface protein, CbpA. Expression of this 
protein is highly regulated. The bacteria transit cells of the cerebral 
microvasculature within a vacuole without intracellular multiplica- 
tion and enter the cerebrospinal fluid space. 
Death of glia and neurons is responsible for the sequelae of disease. 
Pneumolysin, a potent cytotoxin in the lung, is not required for this 
process in the CNS. Injury in the hippocampus I is prominent and 
involves caspase activation and classical apoptosis. This is particularly 
evident in the dentate gyrus, and neuronal and microglial cell death 
is attenuated in a rabbit meningitis model by inhibitors of caspase 
activation. The apoptosis requires participation of elements of the 
host inflammatory response. Other areas of the bran undergo a 
second type of apoptotic mechanism driven by the pneumococcus. 
Thus, preventing sequelae of pneumococcal meningitis may involve 
antibiotics and addition of apoptosis inhibitors in conjunction with 
down-modulation of inflammation. 
Prevention of infections in 
immunocompromised patients 
[s1061 Prevention of bacterial infections in cancer 
patients 
C. Viscoli. University of Genoa, Institutefor Cancer Research, Genoa, 
Italy 
Several procedures (from reverse isolation to total protective isolation 
with LAF rooms) have been proposed for the prevention of infection 
in cancer patients. However, most of these procedures are not cost- 
effective, so that standard precautions, including careful hand- 
washing and appropriate management of IV lines, remains the only 
effective method for preventing bacterial infections in this patient 
population. Isolation measures should rather be aimed at preventing 
the spread of transmissible diseases or multiresistant organisms within 
the hospital. Chemoprophylaxis with non-absorbable (total or 
selective intestinal decontamination) and absorbable antibiotics 
(selective decontamination+systemic prophylaxis) has also been 
studied and used extensively. Poor compliance, risk of recolonization 
with resistant organisms, development of resistance and lack of 
efficacy on pragmatic endpoints are common problems encountered 
with chemoprophylaxis. The most popular drugs that have been used 
(and are still used) are the Auoroquinolones. Indeed, these drugs were 
shown to provide a consistent reduction in the incidence of Gram- 
negative bacteremia, although with no effect on, or even an causing 
an increase in, Gram-positive bacteremia. Moreover, almost no study 
showed any effect on ‘strong’ endpoints, such as mortality, fever and 
need to use IV antibiotics. Finally, resistance to fluoroquinolones 
started to spread rapidly, especially amongst E. coli and staphylococci. 
Cancer patients are not all the same and high-risk patients might have 
benefited (and might still benefit) from prophylaxis. Unfortunately, 
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quinolone prophylaxis has been used indiscriniinately in low- and 
high-risk patients and this has been a mistake. Future approaches 
should select patient populations that are more likely to benefit from 
prophylaxis. 
Poster or  oral presentation prcfirrcd 
[s107] Prevention and treatment of CMV infection in 
stem cell transplant recipients: strategies and 
challenges 
P. Keusser. Departwimt .f Medicine, Chiversify Hospital, Basel, 
Switzerland 
Patients after stem cell transplantation (SCT) are at increased risk for 
cytoniegalovirus (CMV) infection and serious CMV disease during 
the period of profound immunodeficiency early after transplantation. 
In recent years, efficient strategies for the management of CMV 
infection and disease in SCT recipients have been developed. Progress 
was made possible by the introduction into clinical use of rapid and 
sensitive diagnostic methods and of potent antiviral drugs against 
CMV Primary CMV infection is best prevented by the exclusive use 
of seronegative or leukocyte-depleted blood products if the stem cell 
donor is CMV seronegative. CMV disease due to reactivation of 
latent virus can be prevented by preemptive treatment of CMV 
infection with intravenous ganciclovir. but this drug is associated with 
important marrow toxicity. If the initiation of treatment i5 based on 
positive CMV antigeneniia or P C R  in peripheral blood specimens, 
which are methods that detect CMV infection at an earlier stage than 
the shell-vial assay, the duration of  ganciclovir niay be shortened, 
thereby reducing the risk of severe neutropenia. Foscarnet, which is 
equally effective against CMV hut which lacks niajor bone inarrow 
toxicity, niay prove to be a valuable alternative in the preemptive 
treatnic'nt of CMV infection after SCT. A randomized coinparison 
of foscarnet and ganciclovir for preemptive treatment of CMV 
infection was recently concluded among the centers of the European 
Group for Blood and Marrow Transplantation (EBMT), and reqults 
of this trial should become available soon. Prophylaxis of CMV 
infection after SCT is also carried out by using high-dose intravenous 
acyclovir, which was shown to he safe but only partially effective in 
preventing CMV disease in these patients. A recent study of 
valaciclovir prophylaxis for CMV infection after allogeneic SCT 
showed a significant reduction of CMV vireniia but no difference in 
the incidence of CMV disease or in the mortality when coinpared 
to acyclovir prophylaxis. The role of passive iinrnunization in the 
prevention of CMV infection and disease after SCT remains contro- 
versial, and in view of the unclear benefit and of the important costs 
of immune globulin infusions, this approach cannot be advocated for 
routine use without further investigations. The  therapy of established 
CMV piieumonia after SCT currently consists of combining 
ganciclovir with high-dose intravenous irninune globulins, which 
induces a treatment response in approximately 60'% of patients, but 
the long-term survival rate is only about 3tI% Thus, iiiajor emphnsis 
must be placed on preventing CMV disease in SCT recipients. The  
emergence of CMV strains resistant to antiviral drug treatment is 
being reported with increasing frequency and is of concern. The  
incidence and best alternative therapy of disease due to resistant CMV 
after SCT need to be determined. Future studies niay furthermore 
help to clarify the role of novel antiviral agents, such as cidofovir, 
valganciclovir, lobucavir, and the derivative of compound 1263W9.1, 
in the prevention and preeniptive treatment of CMV infection in 
patients after SCT. Moreover, new approaches to prevention ofCMV 
infection, such as adoptive inimunotherapy with CMV-specific 
cytotoxic T-lymphocyte clones, need to be further investigated. 
HSV and VZV infection in 
immunocompromised patients 
M. Hoeckh. Fed  Hirtr/riir.wn Caiiccr Rcs. G i w q  l~$rrti~ins Di.reuscs, 
Scatrlc, 12:4, USA4 
Major progress has been mads in thc m~ir,~gcment of HSV and VZV 
infections in ininiunvcoiiiproniised patients over the List 15 years. In  
transplant patients, especially niarrow transplant recipirnts, acyclovir 
prophylaxis IS now routinely given to HSV-seropositive rccipieiit\. 
Thi\ has virtually eliminated serious complications of HSV infections 
during the period of highest risk of reactivation. However, recurrent 
HSV infection continues to occui. after discontinuation of acyclovir, 
mainly in patients with continued inimutiosuppression. Recurrent 
HSV infection inay be associated with developiiient of drug 
resistance. Foscarnet has been used successfully 111 cases of acyclovir 
resistance. VZV infections are coiiiinon in both transplant and HIV- 
infected patients, Treatment with high-dose acyclovir is usually 
successful, but cases with fatal or complicated outconies continue to 
occur, especially when the clinical presentation is atypical and/or 
treatment is instituted late during the course. Such clinical situations 
include abdominal presentations without skin lesions after niarrow 
transplantation. This overview will discuss current issues of HSV and 
VZV infections in iinniunocomprotiii\ed patients, including the 
recent epidemiology in transplant recipients and HIV-infected 
patients receiving potent antiretroviral therapy, clinical nianifest- 
ations, immunobiology, diagnosis, pharrnacologic agents, drug re\ist- 
ance, immunization, and current prevention and treatment strategies. 
Next generation quinolones for a new 
therapeutic millennium 
ISlll( Structural determinants of quinolone potency 
and bacterial resistance 
D.C. Hooper. dlnrsar/lrrsctts Genenil Hospitnl, Boston, hL4, C7S.4 
The potency of the quinoloncs is detemmined by their activity in 
stabilizing DNA complexes with DNA gyrase and topoisomerase IV, 
bacterial enzymes with distinct and essential role\ in DNA cynthesis, 
and by their ability to permeate cell nienibraiies and avoid eRlux to 
reach these targets. Potency also affects the ritk of development of 
bacterial resistance. For quinolones with a high therapeutic index, 
selection of mutants at clinically relevant concentratioiis may he low. 
Resistance may decrease for quinolones with balanced activity against 
both target enzymes and for those that are poor substrates for bacterial 
iiiultidrug eff7ux puiiips. The activity of quinohnrs again\t Grant- 
negative bacteria is enhanced by the addition of a fluorine a t  po\ition 
6 and J piperazine at position 7. The cyclopropyl group a t  pwition 
3 also enhances potency Other quinolone modifications haw led to 
the newest agents with enhanced activity againft Gram-positivc 
pathogens and anaerobes and preserved potency against Gram- 
negative bacteria. Improvement of Grain-pos~tive activity 111 \o~i ie  
cases correlates with enhanced potency against topoironierase IV 
Potency is increased by alkylation of the pipcrziiiyl group or 
substitution of I? pyrrolidinyl group a t  position 7, amino or methyl 
subqtituents at position 5, and halides or inethoxy groups at po\ition 
8. These latter substituents also improve maerobic activity. The latect 
generation of quinolones with such changes have fiirther iiiiproved 
potency and breadth of spectrum, rivaling those of carhapenem\. 
These modifications also result in compounds with iiiore closely 
balanced activities against DNA gyrase and topoisonierasc IV and 
some with substantially lower frequencies of resistance in vitro. It 
